Related Experiment Video

Updated: Sep 19, 2025

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.3K

Sodium-Glucose Co-transporter-2 Inhibitors and Cardiac Function Parameters: A Network Meta-analysis and Trial

Kannan Sridharan1, Gowri Sivaramakrishnan2

  • 1Department of Pharmacology & Therapeutics, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.

Current Reviews in Clinical and Experimental Pharmacology
|June 18, 2025
PubMed
Abstract

Insights

Sodium-glucose Co-transporter-2 Inhibitors (SGLT2is) improve cardiac function in heart failure patients. This meta-analysis shows SGLT2is enhance left ventricular ejection fraction and reduce cardiac mass, supporting their guideline recommendations.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Sodium-glucose Co-transporter-2 Inhibitors (SGLT2is) are recommended for heart failure management based on clinical outcomes.
  • Limited evidence exists linking SGLT2is to specific changes in cardiac function parameters.

Purpose of the Study:

  • To systematically evaluate the impact of SGLT2is on various cardiac function parameters.
  • To synthesize evidence from randomized clinical trials on SGLT2i effects on cardiac metrics.

Main Methods:

  • Systematic review and meta-analysis of 34 randomized clinical trials involving 2930 participants.
  • Pooled estimates of mean differences (MD) with 95% confidence intervals (95% CI) using random-effects models.
  • Validation through trial sequential and bootstrap analyses; subgroup analysis for heart failure.

Main Results:

  • SGLT2is significantly increased left ventricular ejection fraction (MD: 0.73%).
  • SGLT2is significantly reduced left ventricular mass, mass index, end-diastolic diameter, end-diastolic volume, left atrial volume index, and pulmonary artery systolic pressure.
  • Significant improvements in cardiac parameters were noted in heart failure subgroups.

Conclusions:

  • Findings support current guidelines recommending SGLT2 inhibitors for heart failure.
  • SGLT2is demonstrate beneficial effects on cardiac function parameters, complementing clinical outcome data.
Keywords:
NMASGLT2iheart failure.left ventricular ejection fraction

More Related Videos

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.9K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

668

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
747
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310